Self-reported healthcare decision-makers' attitudes towards economic evaluations of medical technologies

Current Medical Research and Opinion

Volumn 24, Issue 11, 2008, Pages 3049-3058

  Galani, Carmen ^a,b   Rutten, Frans F H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Decision making; Health economics; Health policy; Priority setting; Research utilization

Indexed keywords

ATTITUDE; CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FUNDING; HEALTH CARE DELIVERY; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PHYSICIAN; REVIEW; SELF REPORT;

ATTITUDE TO HEALTH; DECISION MAKING; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH POLICY; HEALTH RESOURCES; HUMANS; SELF REPORT; TECHNOLOGY, MEDICAL;

EID: 67649408931     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802442695     Document Type: Review

References (71)

1. Shiell A, Donaldson C, Mitton C, et al. Health economic evaluation. J Epidemiol Community Health 2002;56:85-88 (Pubitemid 34098457)
2. Rubin RM, Chang CF. A bibliometric analysis of health economics articles in the economics literature: 1991-2000. Health Econ 2003;12:403-1141
3. Schreyögg J, Stargardt T, Velasco-Garrido M, et al. Defining the 'Health Benefit Basket' in nine European countries. Evidence from the European Union Health BASKET Project. Eur J Health Econ 2005;(Suppl):2-10. (Pubitemid 41704928)
4. García-Alonso MD, García-Mariñoso B. The strategic interaction between firms and formulary committees: effects on the prices of new drugs. J Health Econ 2008;27:377-404
5. Cohen J, Stolk E, Niezen M. The increasingly complex fourth hurdle for pharmaceuticals. Pharmacoeconomics 2007;25:727-734 (Pubitemid 47481638)
6. Weart W, Bauman GR. The case for a value-based formulary: striving for total lowest net cost. Manag Care Interface 2007;20:42-47 (Pubitemid 46640555)
7. Chauhan D, Mason A. Factors affecting the uptake of new medicines in secondary care - a literature review. J Clin Pharm Ther 2008;33:339-348
8. Anell A, Svarvar P. Pharmacoeconomics and clinical practice guidelines: a survey of attitudes in Swedish formulary committees. Pharmacoeconomics 2000;17:175-185 (Pubitemid 30148814)
9. Bloom BS. Use of formal benefit/cost evaluations in health system decision making. Am J Manag Care 2004;10:329-335 (Pubitemid 38623524)
10. Bryan S, Williams I, Mciver S. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. Health Econ 2007;16:179-193 (Pubitemid 46206612)
11. Buusman A, Andersen M, Merrild C, et al. Factors influencing GPs' choice between drugs in a therapeutic drug group. A qualitative study. Scand J Prim Health Care 2007;25:208-213 (Pubitemid 350179031)
12. Cox E, Motheral B, Griffis D. Relevance of pharmacoeconomics and health outcomes information to health care decision-makers in the United States. Value Health 2000;3:162
13. DeRoeck D. The importance of engaging policy-makers at the outset to guide research on and introduction of vaccines: the use of policy-maker surveys. J Health Popul Nutr 2004;22:322-330 (Pubitemid 39585866)
14. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the UK. Soc Sci Med 1997;45:583-595 (Pubitemid 27353079)
15. Duthie T, Trueman P, Canlellor J, et al. Research into the use of health economics in decision making in the United Kingdom - Phase II. Is health economics 'for good or evil'? Health Policy 1999;46:143-157
16. Erkan D, Yazici Y, Harrison MJ, et al. Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: the impact of cost on first-line therapy. Arthritis Rheum 2002;47:285-290 (Pubitemid 34627697)
17. Evans C, Dukes EM, Crawford B. The role of pharmacoeconomic information in the formulary decision-making process. Journal of Managed Care Pharmacy 2000;6:108-121
18. Fattore G, Tobirca A. Economic evaluation in health care: the point of view of informed physicians. Value Health 2006;9:157-167
19. Fijn R, Brouwers JR, Knaap RJ, et al. Drug and Therapeutics (D & T) committees in Dutch hospitals: a nation-wide survey of structure, activities, and drug selection procedures. Br J Clin Pharmacol 1999;48:239-246
20. Ginsburg ME, Kravitz RL, Sandberg WA. A survey of physician attitute concerning cost-effectiveness in patient care. West J Med 2000;173:390-394 (Pubitemid 32041605)
21. Gabrowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Soc Sci Med 1997;45:535-544 (Pubitemid 27353075)
22. Greenberg D, Peterburg Y, Vekstein D, et al. Decisions to adopt new technologies at the hospital level: insights from Israeli medical centers. Int J Technol Assess Health Care 2005;21:219-227 (Pubitemid 40656551)
23. Grizzle A, Motheral B, Garrity B, et al. A qualitative assessment of managed care decision-makers's views and use of pharmacoeconomic information. Value Health 2000;3:162-163
24. Hasle-Pham E, Arnould B, Späth HM, et al. Role of clinical, patient-reported outcome and medico-economic studies in the public hospital drug formulary decision-making: results of a European survey. Health Policy 2005;71:205-212 (Pubitemid 39647631)
25. Hoffman C, Schulenburg JMG. The influence of economic evaluation studies on decision making. A European survey. Health Policy 2000;52:179-192
26. Hoffmann C, Stoykova BA, Nixon J, et al. Do health-care decision makers find economic evaluations useful? The findings a of focus group research in UK health authorities. Value Health 2002;5:71-78 (Pubitemid 34274864)
27. Iglesias CP, Drummond MF, Rovira J. Health-care decision-making process in Latin America: problems and prospects for the use of economic evaluation. Int J Technol Assess Health Care 2005;21:1-14 (Pubitemid 40229363)
28. Jacoby A, Smith M, Eccles M. A qualitative study to explore influences on general practitioners' decisions to prescribe new drugs. Br J Gen Pract 2003;53:120-125 (Pubitemid 36187498)
29. Jansson S, Anell A. The impact of decentralized drug-budgets in Sweden - survey of physicians' attitudes towards costs and cost-effectiveness. Health Policy. 2006;76:299-311
30. Jenkings KN, Barber N. What constitutes evidence in hospital new drug decision making. Soc Sci Med 2004;58:1757-1766 (Pubitemid 38281141)
31. Kangis P, van der Geer L. Pharmaco-economic information and its effect on prescriptions. J Manag Med 1996;10:66-74
32. Luce BR, Brown RE. The use of technology assessment by hospitals, health maintenance organizations, and third-party payers in the United States. Int J Technol Assess Health Care 1995;11:79-92
33. Luce BR, Lyles A, Rentz AM. The view from managed care pharmacy. Health Affairs 0000;15:168-176 (Pubitemid 126434366)
34. Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Soc Sci Med. 1997;45:511-521 (Pubitemid 27353073)
35. Martin DK, Pater JL, Singer PA. Priority-setting decisions for new cancer drugs: a quantitative case study. The Lancet 2001;358:1676-1681 (Pubitemid 33124325)
36. Martin DK, Hollenberg D, MacRae S, et al. Priority setting in a hospital drug formulary: a qualitative case study and evaluation. Health Policy 2003;66:295-303 (Pubitemid 37433960)
37. Marx S, Wong P, Priory S. Great research or lack of training. ISPOR Connections 2007;13:19-20
38. McDonald R, Burrill P, Walley T. Managing the entry of new medicines in the National Health Service: health authority experiences and prospects for primary care groups and trusts. Health Soc Care Community 2001;9:341-347 (Pubitemid 33696678)
39. Motheral B, Grizzle A, Amstrong E, et al. A national survey of decision-makers in managed care on their views and use of pharmacoeconomic information. Value Health 2000;3:163
40. Nichol MB, Knight TK, Epstein J, et al. Opinions regarding the academy of managed care pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufactures. Journal of Managed Care Pharmacy 2007;13:360-370 (Pubitemid 46958753)
41. Nuijten MJC, Szende A, Kosa J, et al. Health care reform in six Central European countries. A focus on health economic requirements in the drug pricing and reimbursement process. Eur J Health Econ 2003;4:286-291 (Pubitemid 38081992)
42. Odedina FT, Sullivan J, Nash R, et al. Use of pharmacoeconomic data in making hospital formulary decisions. Am J Health-Syst Pharm 2002;59:1441-1444 (Pubitemid 34887078)
43. PausJenssen AM, Singer PA, Detsky AS. Ontario's formulary committee. How recommendations are made. Pharmacoeconomics 2003;21:285-294
44. Prosser H, Walley T. A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing. Soc Sci Med. 2005;60:1335-1346 (Pubitemid 40038762)
45. Ross J. The use of economic evaluation in health care: Australia's decision maker's perceptions. Health Policy 1995;31:103-110
46. Schumock GT, Walton SM, Park HY, et al. Factors that influence prescribing decisions. Ann Pharmacother 2004;38:557-562 (Pubitemid 38352213)
47. Shalansky SJ, Virk R, Ackman M, et al. Access to new cardiovascular therapies in Canadian hospitals: a national survey of the formulary process. Can J Cardiol 2003;19:173-179 (Pubitemid 36401728)
48. Singer PA, Martin DK, Giacomini M, et al. Priority setting for new technologies in medicine: qualitative case study. Br Med J 2000;321:1316-1318
49. Sloan FA, Whetten-Goldstein K, Wilson A. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis. Soc Sci Med 1997;45:523-533 (Pubitemid 27353074)
50. Spath HM, Charavel M, Morelle M, et al. A quantitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey. Pharm World Sci 2003;25:269-275 (Pubitemid 37498932)
51. Steiner CA, Powe NR, Anderson GF, et al. The review process used by US health care plans to evaluate new medical technology for coverage. J Gen Intern Med 1996;11:294-302 (Pubitemid 26174600)
52. Tan EL, Day RO, Brien JE. Prioritising drug and therapeutics committee (DTC) decisions: a national survey. Pharm World Sci 2007;29:90-96 (Pubitemid 46318737)
53. Tordoff JM, Murphy JE, Norris PT, et al. Use of centrally developed pharmacoeconomic assessments for local formulary decisions. Am J Health-Syst Pharm 2006;63:1613-1618 (Pubitemid 44413519)
54. Ubel PA, Jepson C, Baron J, et al. The influence of cost-effectiveness information on physicians' cancer screening recommendations. Soc Sci Med 2003;56:1727-1736 (Pubitemid 36299237)
55. Vuorenkoski L, Toiviainen H, Hemminki E. Drug reimbursement in Finland-a case of explicit prioritizing in special categories. Health Policy 2003;66:169-177 (Pubitemid 37329738)
56. Walley T, Barton S, Cooke J, et al. Economic evaluations of drug therapy: attitudes of primary care prescribing advisers in Great Britain. Health Policy 1997;41:61-72 (Pubitemid 27297923)
57. Weatherly H, Drummond M, Smith D. Using evidence in the development of local health policies. Some evidence from the United Kningdom. Int J Technol Assess Health Care 2002;18:771-781 (Pubitemid 36125883)
58. Williams I, Bryan S, McIver S. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach. J Health Serv Res Policy 2007;12:73-79 (Pubitemid 46733207)
59. Williams IP, Bryan S. Cost-effectiveness analysis and formulary decision making in England: findings from research. Soc Sci Med 2007;65:2116-2129 (Pubitemid 47593038)
60. West R, Borden EK, Collet JP, et al. 'Cost-effectiveness' estimates result in flawed decision-making in listing drugs for reimbursement. Can J Public Health 2002;93:421-425
61. Wu O, Knill-Jones R, Willson P, et al. The impact of economic information on medical decision making in primary care. J Eval Clin Pract 2004;10:407-411 (Pubitemid 39093748)
62. Zwart-van Rijkom JE, Leufkens HGM, Busschbach JJV, et al. Differences in attitudes, knowledge and use of economic evaluations in decision-making in the Netherlands. The Dutch results from the EUROMET project. Pharmacoeconomics 2000;18:149-160
63. Jönsson B. Health technology assessment: regulators or payers - who will take the lead? Clin Ther 2008;30:960-963
64. Kernick DP. The impact of health economics on healthcare delivery. A primary care perspective. Pharmacoeconomics 2000;18:311-315
65. Drummond M, Brown R, Fendrick AM, et al. Use of pharmacoeconomics information - report of the ISPOR Task Force on use of pharmacoeconomic/health economic information in health-care decision making. Value Health 2003;6:407-416 (Pubitemid 36929727)
66. van Velden ME, Severens JL, Novak A. Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels. Pharmacoeconomics 2005;23:1075-1082 (Pubitemid 41633400)
67. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 2006;24:1133-1142 (Pubitemid 44683369)
68. Neumann PJ, Palmer JA, Daniels N, et al. A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care 2008;14:185-188
69. Ryan M, Yule B, Bond C, et al. Scottish general practitioners' attitudes and knowledge in respect of prescribing costs. Br Med J 1990;300:1316-1318 (Pubitemid 20164767)
70. Orvain J, Xerri B, Matillon Y. Overview of health technology assessment in France. Int J Technol Assess Health Care 2004;20:25-34 (Pubitemid 38656958)
71. Niessen LW, Grijseels E, Koopmanschap M, et al. Economic analysis for clinical practice - the case of 31 national consensus guidelines in the Netherlands. J Eval Clin Pract 2007;13:68-78 (Pubitemid 46238798)